Literature DB >> 16314613

New targets, therapies, and toxicities: lessons to be learned.

Walter M Stadler.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16314613     DOI: 10.1200/JCO.2005.04.2408

Source DB:  PubMed          Journal:  J Clin Oncol        ISSN: 0732-183X            Impact factor:   44.544


× No keyword cloud information.
  5 in total

Review 1.  Targeted cancer therapy: interactions with other medicines.

Authors:  D Conde-Estévez
Journal:  Clin Transl Oncol       Date:  2016-04-25       Impact factor: 3.405

2.  Phase I and pharmacological study of the broad-spectrum tyrosine kinase inhibitor JNJ-26483327 in patients with advanced solid tumours.

Authors:  I R H M Konings; M J A de Jonge; H Burger; A van der Gaast; L E C van Beijsterveldt; H Winkler; J Verweij; Z Yuan; P Hellemans; F A L M Eskens
Journal:  Br J Cancer       Date:  2010-09-07       Impact factor: 7.640

3.  Novel therapies in advanced renal cell carcinoma: management of adverse events from sorafenib and sunitinib.

Authors:  Philipp Ivanyi; Thomas Winkler; Arnold Ganser; Christoph Reuter; Viktor Grünwald
Journal:  Dtsch Arztebl Int       Date:  2008-03-28       Impact factor: 5.594

Review 4.  Targeted therapy for advanced renal cell carcinoma.

Authors:  C Coppin; L Le; F Porzsolt; T Wilt
Journal:  Cochrane Database Syst Rev       Date:  2008-04-16

5.  Targeted therapy for metastatic renal cell carcinoma.

Authors:  Fabian Hofmann; Eu Chang Hwang; Thomas Bl Lam; Axel Bex; Yuhong Yuan; Lorenzo So Marconi; Börje Ljungberg
Journal:  Cochrane Database Syst Rev       Date:  2020-10-14
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.